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Upon activation Nod-like receptors (NLRs) assemble into multi-protein complexes such as
the NODosome and inflammasome. This process relies upon homo domain interactions
between the structurally related Pyrin and caspase-recruitment (CARD) domains and adap-
tor proteins, such as ASC, or effector proteins, such as caspase-1. Although a variety of
NLRP and NLRC complexes have been described along with their activating stimuli and
associated proteins, less familiar are processes limiting assembly and/or promoting disso-
ciation of NLR complexes. Given the importance of limiting harmful, chronic inflammation,
such regulatory mechanisms are significant and likely numerous. Proteins comprised of a
solitary Pyrin domain (Pyrin-only) or CARD domain (CARD-only) posses an obvious potential
ability to act as competitive inhibitors of NLR complexes. Indeed, both Pyrin-only proteins
(POPs) and CARD-only proteins (COPs) have been described as regulators of caspase-1
and/or NLR-inflammasome activation and not surprisingly as factors mediating pathogene-
sis. Although clear examples of pathogen encoded POPs are currently limited to members
of the poxviridae, the human genome likely encodes three POPs (POP1, POP2, and a
potential POP3), of which only POP2 is known to prevent NLR:ASC interaction, and three
COPs (COP/Pseudo-ICE, INCA, and ICEBERG), initially described for their ability to inhibit
caspase-1 activity. Surprisingly, among eukaryotic species POPs and COPs appear to be
evolutionarily recent and restricted to higher primates, suggesting strong selective pres-
sures driving their emergence. Despite the importance of understanding the regulation of
NLR functions, relatively little attention has been devoted to revealing the biological impact
of these intriguing proteins. This review highlights the current state of our understanding
of POPs and COPs with attention to protein interaction, functions, evolution, implications
for health and disease, and outstanding questions.
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INTRODUCTION
Inflammation is a non-specific, physiological response of the
immune system to infection and injury. Acute inflammation
occurs within a few minutes following the injury of tissues. This
process is initiated by tissue-associated cells, such as resident
macrophages, that release inflammatory mediators, increase per-
meability of the blood vessels, and subsequently recruit phagocytes
to the affected sites, eliminating not only invading organisms but
damaged tissues as well. Although acute inflammation is normally
self-limiting and beneficial for host defense and healing, excessive
inflammation or prolonged (chronic) inflammation is deleterious
and a cardinal, if not causative, feature of many diseases.
Among the mediators of inflammation, IL-1β is a prominent
pro-inflammatory cytokine produced primarily by myeloid cells
that efficiently stimulates the expression of other gene products,
such as IL-6 and acute phase proteins associated with inflamma-
tion, thus initiating a self-amplifying cytokine network (1). IL-1β
is also key to the fever response and vascular changes accompa-
nying inflammation. It is well-known that IL-1β, together with
the closely related cytokine IL-18, is matured through catalytic
processing by caspase-1, an event associated with the assembly of
multi-protein, caspase-1 activating complexes known as inflam-
masomes. A closely related protein complex, the NODosome, also
promotes inflammation through activation of transcription fac-
tors promoting expression of the proform of IL-1β as well as other
inflammatory cytokines including TNFα and IL-6 [reviewed in
(2)]. Moreover, an increasing number of publications highlight the
importance of various specific inflammasome/NODosome com-
plexes in not only normal inflammatory responses, but in human
pathologies ranging from metabolic disorders to autoimmune
diseases and cancer [reviewed in (3–5)].
Most inflammasomes (and all NODosomes) result from
the activation of intracellular sensor proteins belonging to
the nucleotide-binding, leucine-rich repeat (LRR), or NOD-like
receptor family (NLR). NLR agonists include pathogen-derived
molecules [e.g., lipopolysaccharide, muramyl dipeptides (MDPs),
and flagellin] as well as “sterile” substances (e.g., asbestos, sil-
ica, cholesterol, or uric acid crystals) [reviewed in (6, 7)]. The
non-NLR dsDNA sensor AIM2 also seeds an inflammasome com-
plex (8). In all cases, formation of these active complexes requires
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homotypic domain interactions involving Pyrin domains (PYD),
caspase-recruitment (CARD) domains, or both.
Given the broad significance of inflammasomes, understand-
ing their regulation is a topic of critical importance. Beyond
regulation of expression and preventing inflammasome assem-
bly/activation, mechanisms that limit that assembly or favor dis-
assembly of these complexes have obvious implications for con-
trolling inflammasome-mediated inflammation. Interestingly, two
groups of proteins, Pyrin-only proteins (POPs) and CARD-only
proteins (COPs) have been recently described as negative mod-
ulators that impact and likely regulate inflammasome assembly
and/or caspase-1 dependent production of IL-1β. NODosomes
also rely upon CARD domains and their activation may also be
regulated by COPs. Although not well-studied and underappreci-
ated, these molecules are known, or strongly implied, to interfere
with either inflammasome adapter molecule interaction or down-
stream recruitment of caspase-1. In addition, POPs and COPs,
like other PYD and CARD-containing proteins, can influence the
activation of NF-κB.
NOD-LIKE RECEPTORS
Cells are able to recognize and respond to a large array of
common molecules by virtue of a set of diverse, but limited,
pattern recognition receptors (PRRs). PRRs have been charac-
terized into four groups, Toll-like receptors (TLRs), RIG-I-like
receptors (RLRs), AIM2-like receptors (ALRs), and NLRs. While
TLRs, a family of classical transmembrane proteins well-known
as important for recognizing either extracellular or membrane-
encased foreign organisms (9), form the front line of innate
immune sensors, NLRs constitute a second, intracellular line.
The NLR family consists of intracellular soluble proteins that
sense cytosolic pathogen-associated molecular patterns (PAMPs)
as well as a range of environmental- and host-derived stress signals,
also known as danger-associated molecular patterns (DAMPs).
Conserved tripartite-domain proteins, NLRs contain a central
nucleotide-binding and oligomerization domain (NOD, NBD,
NACHT), C-terminal LRR similar to those of TLRs that may
serve as a “sensor domain,” and a N-terminal effector domain.
NLRs are thought to be synthesized in an auto-repressed, inac-
tive form where an intramolecular interaction between the LRR
and NACHT domains is proposed to block NACHT-mediated
oligomerization, thus inhibiting NLR auto-activation (10). Upon
binding (or responding to) respective ligands, the LRRs are
thought to undergo a conformational change allowing NACHT-
dependent oligomerization and recruitment of appropriate adap-
tor proteins, leading to NODosome or inflammasome assembly
(Figure 1).
NODOSOMES
The NLRC (NOD) and NLRP (NALP) subfamilies which con-
tain a CARD or PYD N-terminal effector domain, respectively,
are the most studied NLRs (11). NOD1/NLRC1 (CARD 4) and
NOD2/NLRC2 (CARD 15) were among the first NLRs to be
described (12, 13). NOD1 and NOD2 both detect muropep-
tides released from bacterial peptidoglycan (14). NOD1 binds
to diaminopimelic acid (DAP) (strictly in Gram-negative bacte-
ria), whereas NOD2 directly interacts to MDP (found in both
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FIGURE 1 | NODosome and inflammasome complexes assembled
through CARD–CARD and PYD–PYD homotypic interactions. CARD
domain-dependent direct recruitment of RIP-2 by NLRCs (e.g.,
NOD2/NLRC2) leads to NF-κB activation (left panel) and CARD
domain-dependent direct recruitment of Caspase-1 by NLRC4 leads to
IL-1β/IL-18 processing (middle panel), while PYD domain-dependent
recruitment of the adaptor ASC (PYCARD) leads to CARD
domain-dependent recruitment of Caspase-1 and IL-1β/IL-18 processing
(right panel). (Domains: purple, LRRs; light blue, NBD/NACHT; teal, CARD;
light green, PYD).
Gram-positive and Gram-negative bacteria) (15–18). Upon spe-
cific ligand recognition, NACHT domain oligomerization initiates
recruitment of the CARD-containing kinase RIP-2 through a
homotypic CARD–CARD interaction, leading to the formation
of NODosomes (Figure 1). RIP-2, in turn, activates the IκB kinase
(IKK) complex followed by the subsequent release and nuclear
translocation of NF-κB (12, 19). Beyond NF-κB activation, NOD1
recruitment of RIP-2 is believed to activate c-jun kinase (JNK)
(20, 21).
INFLAMMASOMES
NLRPs represent the largest NLR subfamily and are characterized
by the presence of an N-terminal PYD effector domain (11, 22).
Activation of various NLRPs by specific agonists leads to assembly
of a multi-protein inflammasome complex. During inflamma-
some activation, the activated NLRP recruits the bipartite PYD-
CARD domain protein ASC (also known as PyCARD) though
a PYD–PYD interaction and the CARD domain of ASC subse-
quently recruits the CARD domain of caspase-1 (4) (Figure 1). In
the assembled inflammasome, proximity-induced auto-activation
of the catalytic domain of caspase-1 results in the mature, fully
active caspase-1 followed by proteolytic cleavage and release of IL-
1β and IL-18 (23, 24). Unlike NODosomes, the critical interaction
to assemble NLRP inflammasomes is the PYD–PYD interaction
with ASC. Two typical types of NLRP inflammasomes have been
identified (25, 26). The NLRP1 inflammasome is composed of
NLRP1, the adapter protein ASC, ASC-recruited caspase-1, and
caspase-5 which is recruited through a NLRP1-specific C-terminal
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CARD domain (27). The NLRP3 inflammasome is believed to
represent the arrangement of most NLRP inflammasomes and
contains NLRP3, ASC, and caspase-1, but does not recruit caspase-
5 (28). One other class of NLR-inflammasome is represented by
NLRC4 (Ipaf/Naip5). By virtue of its N-terminal CARD domain,
NLRC4 which is activated by flagellin, is believed to directly recruit
caspase-1 through a CARD–CARD interaction, independent of
ASC (29, 30) (Figure 1). Despite differences in the mode of
caspase-1 recruitment, all of these inflammasomes control the pro-
cessing and activation of the pro-inflammatory cytokines IL-1β
and IL-18.
HOMO-DOMAIN INTERACTION
Pyrin domains and CARD domains are members of the larger
death domain (DD) fold superfamily characterized by the highly
similar secondary structure of an antiparallel, six α-helical bun-
dle (31). Like their close cousins, members of the DD and death
effector domain (DED) family which interact homotypically (32),
it is widely held that PYD- and CARD-containing proteins act
exclusively in similar fashion.
PYRIN DOMAINS
The PYD domain is a conserved sequence motif found in more
than 20 human proteins with putative functions in apoptotic
and inflammatory signaling pathways (33). Studies reporting PYD
structures are rare, due to the limited solubility of these domains
(31). However, several PYDs including those from ASC, POP1, and
NLRP3 have been structurally characterized. All have distinct pos-
itively and negatively charged surface patches in their structure,
leading to the proposal that electrostatic interactions are criti-
cal for PYD interaction (33–36). Notably, the three-dimensional
structure of the human ASC PYD has helped clarify how this adap-
tor protein binds to the PYD of NLRP3 as well as that of POP1 (33,
37). The PYD domain of ASC is a highly bipolar molecule with
most of the positively charged side-chains located in helices 2 and
3 and the connecting loop, while most of the negatively charged
side-chains reside in helices 1 and 4 and the immediately adjacent
regions, suggesting that, in analogy to CARD domains, charge-
charge interactions may play an important role in PYD domain
interactions (38). In fact, the negative residues on the ASC PYD
Asp6, Asp10, Asp51, and Asp54 play important role in the interac-
tion between ASC and POP1. Consistently, at least two positively
charged amino acids in POP1, including Lys21 and Arg41, were
required for this association (39).
CARD DOMAINS
CARD domains are thought to homotypically interact in a fash-
ion similar to PYDs. Structural studies of adaptor proteins such
as RAIDD and the NLR-like apoptosome protein Apaf-1 revealed
that CARD domains also contain distinct basic and acidic patches
(38, 40–42), suggesting an electrostatic nature for CARD–CARD
interaction. Indeed, the acidic surface of the Apaf-1 CARD located
in helices 2 and 3 is necessary for interaction between Apaf-
1 and caspase-9 (38, 42). In addition, hydrophobic interactions
are also an important driving force underlying this particular
CARD/CARD interaction (42).
REGULATION OF NLR ASSEMBLY BY POPs AND COPs
Based on our current knowledge of NLR assembly, it is likely
that one powerful way to modulate the assembly of NODosomes
and inflammasomes is the disruption of PYD and CARD homo-
domain interactions. The growing POPs and COPs families (as
discussed in detail below) are potential modulators of inflam-
masome and NODosome assembly and are likely important to
understanding NLR-associated diseases.
Pyrin-only proteins and COPs are relatively short proteins of
approximately 90 amino acids composed essentially of only a PYD
or CARD domain. Accordingly, they are structurally and function-
ally related, and as expected, homotypic interactions appear key
to their inhibitory effects in regulating NLR assembly. The cur-
rently known POPs and COPs and their known or likely roles in
regulation of NLR complexes are depicted in Figure 2.
PYRIN-ONLY PROTEINS
To date, two POPs have been characterized based following initial
identification in the human genome using bioinformatic mining.
These include POP1 (PYDC1) and POP2 (PYDC2). An evolu-
tionary analysis of POP2 suggests the possibility of a third POP
within the NLRP2P pseudogene locus (43). Both appear to have
resulted from either gene duplication (POP1) or retrogene inser-
tion (POP2) from PYD-encoding genes already present in an
ancestral primate genome (43, 44) and thus do not represent
lateral gene transfer of viral PYD sequences. Both POPs exhibit NF-
κB modulating activity, but contrary to numerous reviews which
incorrectly ascribe inflammasome inhibitory properties to POP1,
only POP2 is known to inhibit inflammasome assembly. Curiously,
POP:PYD targets COP:CARD targets
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FIGURE 2 | Known and likely targets for human POPs and COPs. Left
panel, only POP2 is known to limit assembly of certain NLRP
inflammasomes but whether POP2 restricts all NLRP inflammasomes is
unknown. POP1 may be able to inhibit some NLRP:ASC interactions, but
these remain unknown. While POP3 may likely be unable to bind ASC,
whether it might interact with an NLRP PYDs remains to be determined.
Right panel, INCA, ICEBERG, and COP/Pseudo-ICE all bind pro-Caspase-1
and should inhibit all NLRP and NLRC inflammasome, however, no specific
inflammasome targets have been examined. However, only
COP/Pseudo-ICE interacts specifically with the CARD of RIP-2, thus it may
be a singular regulator of NODosomes.
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certain myxoma viruses belonging to the poxviridae employ POPs
(vPOPs) as pathogenic determinants.
POP1
In an early bioinformatics screen for Pyrin-containing sequences,
Stehlik et al. discovered the first POP1, initially designated ASC2
due to the high degree of similarity with the ASC PYD domain
(44, 45). The POP1 gene is located on chromosome 16p12.1 and
consists of two exons interrupted by a 580 bp intron, where the
entire PYD is encoded in a single exon yielding an 89 amino
acid sequence which is 64% identical (88% similar) to the PYD
domain of ASC (44). Expressed predominantly in monocytes,
macrophages, and granulocytes, POP1 is implicated in regulat-
ing inflammation. POP1 inhibits NF-κB activation by a variety of
stimuli, including TNFα, IL-1β, Nod1, and Bcl-10, in HEK-293,
COS-7, and Hela cells (44). POP1 interacts with the PYD of ASC
and also suppresses NF-κB activity stimulated by co-expression of
ASC and pyrin or NLRP3. The capacity of co-transfected POP1
to inhibit NF-κB activation induced by various proteins including
TRAF2, TRAF6, the TRAF-binding kinase TBK1, the IKK com-
plex constituents IKKα and IKKβ, and by the IKK-related kinase
IKKi, revealed that POP1 modulates NF-κB activation at the level
of the IKK complex, as reported for ASC and for NALP4/NLRP4
(46, 47). Consistently, POP1 associates with the IκBα kinases IKKα
and IKKβ, inhibiting their kinase activity. These associations are
very unlikely to be the result of homotypic domain interactions
as IKKs lack PYD. Instead, a more likely possibility is that POP1
contains small IKK-inhibiting sequence similar to the 23 amino
acid NEMO binding domain (48). It is anticipated, although not
yet demonstrated, that POP1 should inhibit IKK activity down-
stream of the NODosome activation of RIP-2. Although POP1
enhanced ASC-mediated IL-1β activation (44), in a later study,
POP1 did not inhibit either ASC-dependent or NLRP3 inflamma-
some processing of IL-1β (49). Thus, no evidence to date supports
a role for POP1 in inhibiting an inflammasome, consistent with
a structure-predicted inability to regulate NLRP3 inflammasome
activation (39). Taken together, it is likely that POP1 targets NF-κB
activity via inhibition of IKK, but does not act as an inhibitor of
ASC-dependent NLRP inflammasomes. Despite the strong molec-
ular evidence for the function of POP1, there have been no studies
of its function using primary human or POP1-expressing mouse
myeloid cells.
POP2
Following the discovery of POP1, a second human POP (POP2)
was identified simultaneously by two independent groups (50, 51).
POP2 is encoded by a 294 nucleotide, single exon gene located on
human chromosome 3q28 and produces a protein of 97 amino
acids with high similarly to the PYDs of NLRP2 and NLRP7 (78%
similarity, 67% identity to the PYD of NLRP2) (50, 51). POP2 is
expressed in human testis, primary peripheral blood leukocytes,
monocytic cell lines, and is induced in human primary mono-
cytes or monocytic cell lines by a variety of stimuli (PMA, LPS, or
TNF-α) (49, 50), implicating a function in inflammation and host
immunity. Despite the absence of a canonical nuclear localiza-
tion signal sequence, POP2 displays both cytoplasmic and nuclear
expression patterns in transfected cells, suggesting that POP2 may
function in either, or both, compartments (50). As postulated
from observations with POP1 and other PYD-containing proteins,
POP2 diminishes NF-κB activation. As anticipated, POP2 blocks
TNF-α-mediated NF-κB activation (50). However, POP2 inhibits
the activity of transfected NF-κB p65/RelA, indicating that POP2
acts distally in the NF-κB cascade at the level of p65, a function that
POP1 and other PYDs apparently lack. Recent work reveals that
POP2 acts to limit the transactivation potential of the C-terminal
transcriptional activation domain 1 (TAD1) of p65/RelA (49).
How this is accomplished is unclear, but one possibility is a block-
ade of one or more of the kinases responsible for necessary phos-
phorylation events within TAD1 of p65 such that transactivation
potential is reduced. In addition, although POP2 interacts with
ASC, POP2 inhibition of NF-κB p65 is ASC-independent (49).
The interaction of POP2 with ASC leads to formation of a
peri-nuclear “speck” structure similar to that observed with co-
expression of ASC with Pyrin, POP1, various NLRPs, and upon
NLRP3 inflammasome activation (50, 51). Moreover, POP2 also
interacts with several PYD-containing NLRs (NLRP1, 2, 3, and 12)
(50, 51). Indeed, POP2 nearly abolishes the interaction between
ASC and the NLRP3-PYD as well as inhibiting ASC interaction
with NLRP1 and NLRP12 although to a lesser extent (50). Thus,
POP2 may be a broad acting competitive inhibitor of inflamma-
somes. This notion is supported by recent experiments revealing
that POP2 effectively inhibits the non-NLR AIM2 inflammasome
(unpublished observation). Co-expression of POP2 with ASC and
the disease-associated NLRP3 R260W mutant impairs activation
of caspase-1 in a dose-dependent manner (51). NLRP3 R260W
(like other disease producing NLRP3 variants) interacts more
readily/efficiently with ASC leading to caspase-1 activation, even
without an agonist (51), suggesting that POP2 limits on NLRP3
inflammasome activity may not be overcome by activating muta-
tions. POP2 also impairs activation of the NLRP2 inflammasome
(51). These in vitro observations demonstrate the broad potential
of POP2 to disrupt NLRP-ASC interactions and have significant
implications for the in vivo role of POP2.
By generating POP2 truncation mutants with inter-helical stop
codons to maintain the integrity of the remaining helices,Atianand
et al. probed the specific portions of POP2 required for its func-
tion. In this study, the first α-helix of POP2 (residues 1–19) was
shown to be both necessary and sufficient for inhibiting transacti-
vation by NF-κB and for restricting inflammasome assembly (49).
The first α-helix of POP2 has no basic residues but contains three
acidic residues Glu6, Asp8, Glu16 (49). Consistent with the struc-
tural data showing the importance of electrostatic surface patches
(EPSPs) in PYD–PYD interactions (39) mutation of these acidic
residues markedly impairs the ability of POP2 to disrupt inflam-
masome function. NF-κB inhibition is seemingly unaltered by
these mutations, implicating other elements of the first helix which
might reside on the opposite helical face, although this remains to
be established. The ASC adaptor protein has a bipartite charge dis-
tribution, with both positive and negative EPSPs (39). Although
the negative EPSP of ASC was demonstrated to be a POP1 binding
site, the presence of necessary acidic residues in the first α-helix of
POP2 (and another contributing acidic residue in helix 4), leads
to the proposal that helices 1 and 4 of POP2 interact with the
positive EPSP on helix 2 and 3 of the ASC PYD. Interestingly,
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the positive ASC helix 2/3 EPSP was also proposed as the binding
site of NLRP3 (39), suggesting that POP2 inhibits NLRP3 inflam-
masome assembly through competition with NLRP3 for this site
on ASC.
OTHER HUMAN POPs
Our evolutionary analysis of POP2 suggests the possibility of a
third POP (POP3) within the human genome, encoded by an
open reading frame within the NLRP2P pseudogene (43). Based
on sequence similarity, a protein produced by this ORF would be
anticipated to possess the NF-κB inhibitory properties of POP2,
but lack the ability to inhibit the NLRP3 inflammasome as the
acidic residues known to be important for inhibition are non-
charged, non-polar. Unfortunately, the details of this additional
potential POP protein encoding gene await an initial description.
vPOPs
Some viral proteins, such as Myxoma virus protein M013
and Shope fibroma virus protein (SFV-gp013L) have also been
described to inhibit PYD-dependent inflammasomes and impair
NF-κB activity (52–54). Johnston et al. identified the M13L gene
which encodes the PYD-containing protein M013 in Myxoma
virus, a rabbit-specific poxvirus that is the causative agent of the
lethal disease myxomatosis (52). Notably, in the absence of the
M013 vPOP, rabbits readily clear the viral infection and survive,
indicating the key role of M013 in pathogenesis. Interestingly,
genes encoding additional viral POPs closely related to M13L
were found in other poxviruses, including Yaba-like disease virus,
Tanapox virus, Shope fibroma virus (gene S013L, protein gp013),
Mule deer poxvirus, and Swinepox virus, suggesting the conser-
vation of PYD proteins which likely benefit viral replication and
virulence among diverse poxvirus genera (52, 53, 55). As with
human POPs, the vPOPs M013 and gp013L interact directly with
ASC through PYD–PYD interaction, thus preventing activation of
NLRP3, consequently reducing protective bioactive IL-1β, IL-18
production (52, 53). Interestingly, the first 22 amino acids of M013
vPOP were required for ASC binding, formation of peri-nuclear
specks, and subsequent inhibition of caspase-1 activation as seen
with the first α-helix (19 residues) of human POP2 (49, 52). Both
M013 and SFV-gp013L vPOPs impact NF-κB activity. While the
SFV-gp013L vPOP enhances activation of NF-κB independently
of ASC and NLRs (53), M013 vPOP inhibits NF-κB, binds directly
to host NF-κB1, inhibits the translocation of p65 to the nucleus
(54), reminiscent of human POP2 (50). Interaction between M013
vPOP and NF-κB1 may interfere with NF-κB1/p105 degradation
thus preventing p50 release, formation and subsequent nuclear
translocation of the active p50/p65 heterodimer (54). Accordingly,
infection of THP-1 cells with M013-deficient myxoma virus led
to rapid secretion of cytokines such as TNFα, IL-6, and MCP-
1 (54). While the competitive binding of M013 vPOP to ASC
is required for the disruption of NLRP3 inflammasome, as with
POP2 this interaction was dispensable for NF-κB inhibition (56).
The sequence and functional similarity between the first helices of
POP2 and M013 suggests the use of similar dual mechanisms to
provide the presumed beneficial control of inflammation by POP2
but prevent protective anti-viral inflammatory responses through
M013.
SUMMARY
Among the identified human POPs, POP2 is the only one with a
demonstrated capacity to restrain assembly and function of NLR
complexes, although both POP1 and POP2 impact NF-κB signal-
ing. Two distinct interaction surfaces on the first α-helix of POP2
likely account for its unique ability to both limit NF-κB activa-
tion and restrict inflammasome formation. Thus, POP2 is likely a
multifunctional and broadly acting regulator of inflammatory sig-
nal pathways in higher primates, while in contrast, POP1 inhibits
upstream aspects of NF-κB signaling. The biological role of these
POPs, although intriguing and of highly probable significance,
remains less clear. Similar to human POP2, the vPOP M013 also
has a dual role in impairing NF-κB activation and inflammasome
formation, representing a viral strategy to circumvent protective
innate inflammatory responses. Future investigation is needed to
clarify the mechanism(s) by which human as well as viral POPs
modulate NF-κB activity.
CARD-ONLY PROTEINS
The human genome also contains three COPs, COP/Pseudo-ICE
(CARD16), INCA (CARD17 ), and ICEBERG (CARD18) which
most likely arose through gene duplication and as with the POPs
are restricted to higher primates (57). These proteins were initially
identified and described due to sequence similarity with caspase-1
and serve as non-enzymatic decoys regulating caspase-1 activity.
To date, there are no clear demonstrations of viral COPs.
COP/PSEUDO-ICE
The 16th human CARD (CARD 16) was identified as a 97 amino
acid protein consisting of a CARD region (residues 1–91) with 97%
identity to the CARD of caspase-1 (58). This protein is encoded on
chromosome 11p22, in the same region where caspase-1, caspase-
4, caspase-5, and ICEBERG (see below) reside, and is composed
of three exons separated by introns of 631 and 844 bp respec-
tively, such that the majority of the coding sequence and the entire
CARD domain derive from exon 2 (57–59). Since CARD16 con-
tains essentially only a CARD domain, this protein was named
COP or Pseudo-ICE due to its high sequence identity with the
CARD domain of caspase-1 [also known as Interleukin-1β con-
verting enzyme (ICE)] (59). To avoid confusion between COP
and the generic group of COP proteins, we will refer to this pro-
tein as COP/Pseudo-ICE. COP/Pseudo-ICE is expressed mainly
in placenta, spleen, lymph node, and bone marrow and in the
THP-1 cell line (58, 59). Binding caspase-1, RIP-2, and self-
associating through its CARD domain, COP/Pseudo-ICE inhibits
RIP-2-mediated oligomerization of caspase-1, thus blocking the
activation of caspase-1 and subsequent release of mature IL-1β
(58, 59). Overexpression of COP/Pseudo-ICE can trigger NF-κB
induction and enhanced TNF-α-induced NF-κB activation via a
mechanism dependent on the IKK complex (59).
INCA
The newest indentified COP named INCA (Inhibitory
CARD/CARD17) is located on human chromosome 11q22,
between COP/Pseudo-ICE and ICEBERG (57, 60). The predicted
INCA cDNA sequence is composed of four exons and three introns
628, 1092, and 6778 bp in length (60). The open reading frame
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spans the first to the third exon, but as with COP/Pseduo-ICE,
exon 2 encodes most of the open reading frame including the
CARD domain. Exon 4 is non-coding and thus functions as
a 3′-untranslated region (60). Like COP/Pseudo-ICE and ICE-
BERG, although INCA contains 110 amino acids, the essential
CARD domain consists of the first 91 residues and shares 81%
sequence identity with the CARD of caspase-1. INCA is expressed
in a wide variety of human tissues with highest expression in
brain, heart, spleen, lung, and salivary gland. In general, in tissues
expressing INCA, caspase-1 is also expressed, with the excep-
tion of the salivary gland. Interestingly, INCA and caspase-1 are
coordinately upregulated upon stimulation with INF-γ in the
monocytic cell lines THP-1 and U937, however, LPS and TNF-
α which also induce caspase-1, fail to upregulate INCA (60).
INCA does not interact with the NF-κB-activating kinase RIP-
2, but like COP/Pseudo-ICE, INCA can self-associate, bind to
the pro-domain of caspase-1, and cross-associate with the other
COPs (60). Like ICEBERG which also fails to bind RIP-2, INCA
was completely incapable of activating NF-κB itself and does not
inhibit NF-κB activation induced by well-known factors such as
TNF, caspase-1, COP/Pseudo-ICE, or RIP-2. However, INCA sig-
nificantly reduces the release of mature IL-1β from THP-1 cells
(comparable to COP/Pseudo-ICE), probably due to its interaction
with caspase-1 (60).
ICEBERG
EST clone AA046000 contains a 273 bp open reading frame that
codes for a 90-residue protein named ICEBERG (59) which is
53% identical to the CARD domain of human caspase-1 (61).
ICEBERG is detected mainly in placenta and in many human
cell lines and its expression is upregulated by LPS and TNF
in THP-1 monocytes (61). ICEBERG can self-associate, bind to
the pro-domain of caspase-1, and cross-associate with another
COP/Pseudo-ICE through its CARD domain. Although unable to
interact with RIP-2, ICEBERG clearly binds to caspase-1 through
charge–charge interaction between their CARD domains; not sur-
prisingly ICEBERG is unable to activate NF-κB (59, 61). However,
RIP-2 independently binds and activates caspase-1 directly via
CARD–CARD interaction (61, 62) and ICEBERG blocks this inter-
action by binding caspase-1, a competitive inhibition that disrupt
oligomerization of RIP-2 and caspase-1 and consequently inhibits
IL-1β production.
SUMMARY
All three human COPs interact with caspase-1 and thus,
when expressed are anticipated to influence all instances
of inflammasome-elicited IL-1β and IL-18 production. Only
COP/Pseudo-ICE targets events mediated through the CARD
domain of RIP-2. Why three independent regulators are required
and how they differ is largely unknown and unstudied, but their
common expression in the placenta and monocytic cells may
suggest roles in development as well as immunity.
EVOLUTIONARY HISTORY OF POPs/COPs
In the battle between pathogens and host immunity, pathogens,
typically viruses, manifest sophisticated mechanisms to escape the
detection and control of host immune systems. In contrast, the
host defense incessantly develops strategies to eliminate pathogens
without becoming hyper-responsive and causing harm to itself.
Evolution plays a pivotal role in these both processes. Poxviruses
are excellent examples for studying genome evolution. They accu-
mulate point mutations at relatively low rates, whereas gene dupli-
cations, losses, gain by horizontal gene transfer, and recombination
between different viral species occur frequently (55). These events
led to the appearance of several groups of genetic elements known
as host range genes thought to be important for host adaptation
and subverting the host anti-viral response [listed in (55)]. Of
these host range genes, M013 vPOP protein was proposed to be
an evolutionary factor based on its high sequence similarity with
pyrin, particularly within the first 50 residues and its role as a com-
petitive inhibitor of ASC interactions (52, 53). It is possible that
M013 vPOP is the product of ancestral capture, recombination,
and re-assortment events that occurred during co-evolution of
the virus and its host. Interestingly, phylogenetic analyses showed
that, together with Myxoma virus, other poxviruses belonging
to the largest subgrouping of Chord poxviruses possess M013
orthologs. These include Yaba-like disease virus, Tanapox virus,
Shope fibroma virus, Mule deer poxvirus, and Swinepox virus
(55), suggesting a shared evolutionary ancestor that may have
acquired a host PYD domain prior to the divergence of this group
of viruses.
Among mammals, the human genome encodes at least two and
possibly three POPs (POP1, POP2, and the putative POP3) and
syntenic orthologs are present in the genomes of the non-human
primates Pan troglodytes (chimpanzee), Macaca mulatta (rhesus
macaque), Pongo abelii (orangutan) but the NLRP2P locus (POP3)
and a functional POP2 appear to be absent in that of marmosets
(43). Interestingly, POPs were not found in the genomes of mice,
rats, and domestic animals, even though most human NLRPs are
similar to those in other species (11, 43). Taken together, these
observations support the current hypothesis that POPs are evolu-
tionary recent developments in the mammalian genome and may
be limited to hominids and Old World primates. The evolutionary
history of POPs and COPs are summarized in Figure 3.
Although the selective pressures driving the appearance of
human POPs are unknown, their origins and evolutionary path-
ways have been investigated. The POP1 gene is located on chro-
mosome 16p12.1, the same chromosomal band as the ASC gene,
approximately 14 kb away and the PYD of POP1 is most closely
related to that of ASC (88% similarity and 64% identity) (44).
This close proximity as well as the strong sequence similarity
suggests that POP1 arose by gene duplication (44). More interest-
ingly, phylogenetic analysis revealed that both POP2 and NLRP2P
arose from the same ancestor, an NLRP2/7-like gene (designated
Nlrp2 in mouse), most likely through retrogene insertion events
during the course of primate evolution resulting in two dis-
tinct, and seemingly non-functional, pseudogenes (43). Curiously,
during higher primate evolution, POP2 gained a functional pro-
moter, lost the remnants of the non-PYD portions of the ancestral
NLRP2/7-like gene, and acquired a new polyadenylation sites (43).
Despite the sequence similarity, NLRP2 is adjacent to NLRP7 on
chromosome 19 in human and chimpanzee genomes, whereas
POP2 and NLRP2P are located on chromosome 3 and chro-
mosome X, respectively. The distal location and the absence of
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FIGURE 3 |The evolution of POPs and COPs. POPs and COPs emerged
very recently during mammalian evolution and are restricted to primates. All
currently known POPs are present as intact coding regions in the complete
genomes of Old World primates and hominids but are absent from the
complete genomes of mice, non-primates, and, for at least POP2 and POP3,
New World primates. All currently known COPs are primate restricted [an
ICEBERG locus has been reported for the treeshrew a primate ancestor, see
(63)]. Arrows indicate the relative timing of the retro-transposon insertion of
POP2/3 and the duplication events leading to POP1/COPs in an ancestral
primate genome. (ND, not determined; *, non-functional).
introns as well as the presence of stop-codon disrupted NBD and
LRR sequences in the founding primate genomes strongly impli-
cates the retro-transposition of NLRP2/7-like mRNAs yielding
processed pseudogenes.
Chimpanzee POP2 is identical to human POP2 at both the DNA
and protein level (43). Macaque POP2 is highly conserved, but not
identical to the human sequence. Although macaque POP2 retains
both functions of the human protein, it is a less robust inhibitor
which may result from an additional C-terminal 41 amino acid
stretch absent from human and chimpanzee POP2 (43). Among
the New World primates, the marmoset genome contains an
intron-less pseudogene sequence without a start codon with rem-
nants of not only the PYD, but the nucleotide-binding domain
and portions of the LRR sequences, which share identity with
NLRP2/7. Under strong selective pressure during divergence of
New World and Old World primates, the NBD and LRR sequences
were lost to produce a functional POP2, retained in the common
ancestor of macaques and higher primates. Further pressure dur-
ing the emergence of hominids purified the developing POP2 PYD
sequence to yield a version of POP2 with stronger inhibitory activ-
ities on NF-κB and inflammasomes which is invariant between
humans and chimpanzees (43).
The other NLRP2/7-derived pseudogene named CLRX.1/NOD24
(NLRP2P) also contains an open reading frame that may encode
POP3, but unlike POP2 it contains a conserved stop codon that
would preclude PYD helices 4 through 6.
Similar to POPs, the three mammalian COPs (COP, INCA, ICE-
BERG) are also found only in humans and primates (63). No
ortholog has been identified in the same locus in mouse and rat
genome (57). All three COPs are highly homologous with the
CARD domain of caspase-1 and are located on the same chro-
mosome adjacent to caspase-1 (58, 60, 61), suggesting that COPs
emerged by gene duplication. While putative orthologs of COP
and INCA were identified in human, chimpanzee, and Rhesus
macaque, ICEBERG was only found in human and Rhesus mon-
keys despite the earlier divergence of these monkeys from the
human-chimpanzee lineage (57), perhaps owing to the incom-
pleteness of the chimpanzee genome at this locus on chromosome
9. Nevertheless, like POPs, COPs appear restricted to hominids and
primates, suggesting that strong selective pressures, perhaps acting
to control inflammation at both level of cytokine gene transcrip-
tion and processing of IL-1βby inflammasome activated caspase-1,
drove the emergence of at least six independent genes with largely
unexplored and unexplained biological roles.
BIOLOGICAL IMPACT
Given the key role of IL-1β in inflammation, it is not sur-
prising that defective control of the inflammasome appears to
be a feature of many inflammatory diseases. In fact, the ini-
tial description of the NLRP3 inflammasome and clinical inter-
est in defective control of inflammasome activation resulted in
large part from genetic analysis of families with autoinflamma-
tory diseases. These include familial Mediterranean fever (FMF),
Muckle-Wells syndrome (MWS), familial cold autoinflamma-
tory syndrome (FCAS), neonatal-onset multisystem inflamma-
tory disease/chronic infantile neurological cutaneous, and artic-
ular syndrome (NOMID/CINCA) (64–67). Of these, FMF is
the first known disease with associated mutations in the Pyrin
protein, a small non-NLR protein composed of an N-terminal
PYD domain and a C-terminal PRY-SPRY domain (68). Like
NLRPs, Pyrin associates with ASC and may form an inflam-
masome (69, 70), however, most disease-associated Pyrin muta-
tions occur in the PRY-SPRY domain which is functionally
uncharacterized. Unexpectedly, the other hereditary fever syn-
dromes, including FCAS, MWS, CINCA, which range from the
very mild FCAS to the severe and chronic NOMID/CINCA,
are all attributable to NLRP3 (CIAS1/Cryopyrin). Even though
being distinct clinical entities, the majority of disease-associated
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mutations are located in exon 3 which encodes the NACHT
(NBD/NOD) domain (66, 67). It is likely that these mutations
cause spontaneous oligomerization of the NACHT domain due
to decreased interaction with the LRR which are thought to
inhibit auto-activation of NLR-inflammasomes (10) which in
turn results in overproduction of IL-1β and IL-18, leading to
chronic, excessive inflammation. Other inflammation-related dis-
eases have been reported. Blau syndrome and Crohn’s disease
are associated with the CARD-containing NLR, NOD2/NLRC2
with NACHT domain mutations occurring in Blau syndrome
(71), while LRR domain mutations of NOD2 are reported for
Crohn’s disease (13, 72). Moreover, through rapidly growing
clinical and NLR-deficient mouse studies, specific NLRs have
been linked to numerous diseases, including NLRP1 [various
autoimmune diseases (e.g., psoriasis, systemic lupus erythemato-
sus, rheumatoid arthritis, Celiac disease, and type 1 diabetes),
NLRP3 (e.g., gout, atherosclerosis, type II diabetes, rheuma-
toid arthritis, Alzheimer’s, and cancer of the colon and skin),
NLRP6 (e.g., fatty liver disease, inflammatory bowel disease,
and gastric cancer), NLRP12 (atopic dermatitis), and NLRC4
(e.g., gastric cancer and inflammatory bowel disease); reviewed
in (5, 73)]. The non-NLR PYD-containing protein AIM2 also
forms an inflammasome and is implicated in allergy [reviewed
in (5)]. The importance of inflammasomes in complex diseases,
the majority of which have underlying inflammatory etiologies,
underscores the need for tight control of inflammasome activ-
ity as well as other inflammatory signaling pathways to maintain
homeostasis.
In humans, POPs and COPs very likely represent a mechanism
for restraining pro-inflammatory activation events, for terminat-
ing inflammasome signals, or both depending on the specific
protein. Given that POP2 disrupts downstream activation of the
NLRP3 and likely other NLR-inflammasomes and concomitant
release of IL-1β, POP2 may be critically important in establishing
the normal limits of inflammasome activation. This has significant
implications for inflammasome-associated diseases. For example,
mutations in POP2 involving the acidic amino acids of the first
α helix that are important for NLRP3 inflammasome inhibition
may result in diseases similar to those seen with NLRP3 mutations.
Likewise, mutations that diminish expression of POP2 may have
broad effects allowing more ready and sustained activation of var-
ious NLRPs with attendant increased pathologic inflammation.
Gain of function mutations might provide a protective benefit
for NLRP-associated diseases, although diminished inflamma-
tory responses might similarly predispose individuals to infection
or interfere with wound healing. Similarly, COPs directly binds
caspase-1 and therefore interfere with the interaction of caspase-1
with ASC (in inflammasomes) and/or with RIP-2 (in NODsomes).
Consequently, COPs potentially target NLRCs such as NOD1,
NOD2, and NLRC4 as well as NLRPs, and in principle any pathway
requiring a CARD:CARD domain interaction. The combined reg-
ulatory potential of POPs and COPs within NLR biology is thus
staggering. Further, the evolutionary evidence suggests that it is
critical for human survival. Despite the implications, little atten-
tion has been devoted to understanding these small, seemingly
insignificant proteins.
OUTSTANDING QUESTIONS
In light of the profound biological consequences of NLR auto-
activation (chronic inflammation), tight control of NLR pro-
tein functions is critical to provide the delicate balance between
the initiation and perpetuation of immune responses and anti-
inflammation mechanisms. POPs and COPs are preeminent can-
didates as they are able to control of both NF-κB and inflamma-
some activation. However, studies of the mechanism(s) by which
they interfere with these processes are few. Whether POPs and
COPs represent an array of modulators with overlapping functions
or are discrete, sufficient, regulators of different aspects of NF-
κB signaling, and/or inflammasome activity is unknown. Several
outstanding questions are of immediate importance to the field.
Beyond more immediate questions such as which tissues and cells
express POPs and COPs and under what conditions, the question
of what roles POPs and COPs play in normal human physiology
and pathology is the most urgent. Mouse models of POP/COP
in vivo function need to be developed to study these primate-
restricted proteins. Gene association/single nucleotide polymor-
phism studies of human inflammation-related disease without
specific NLR mutations are also likely informative. Whether POPs
and COPs are broadly acting regulators or specific to particu-
lar pathways remains unclear, but the answer certainly resides at
the intersection of mechanistic studies aimed at understanding
the distinctions between family members and the insights pro-
vided from in vivo systems. More broadly, the presence of POPs
and COPs in humans implies fundamental differences in some,
if not many, aspects of NLR biology between mice and humans
that at present remain mysteries. Finally, lessons learned from
the study of POPs and COPs may lead to additional biologics
that can specifically target dysregulated inflammatory processes
mediated through PYD and CARD domain-containing protein
complexes.
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